Suppr超能文献

N-乙酰半胱氨酸对造影剂所致肾损伤发生率的影响:一项系统评价与试验序贯分析

The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: A systematic review and trial sequential analysis.

作者信息

Wang Nelson, Qian Pierre, Kumar Shejil, Yan Tristan D, Phan Kevin

机构信息

Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia.

Department of Cardiology, Westmead Hospital, Sydney, Australia.

出版信息

Int J Cardiol. 2016 Apr 15;209:319-27. doi: 10.1016/j.ijcard.2016.02.083. Epub 2016 Feb 16.

Abstract

BACKGROUND

There have been a myriad of studies investigating the effectiveness of N-acetylcysteine (NAC) in the prevention of contrast induced nephropathy (CIN) in patients undergoing coronary angiography (CAG) with or without percutaneous coronary intervention (PCI). However the consensus is still out about the effectiveness of NAC pre-treatment due to vastly mixed results amongst the literature.

OBJECTIVES

The aim of this study was to conduct a meta-analysis and trial sequential analysis to determine the effects of pre-operative NAC in lowering the incidence of CIN in patients undergoing CAG and/or PCI.

METHODS

A systematic literature search was performed to include all randomized controlled trials (RCTs) comparing NAC versus control as pretreatment for CAG and/or PCI. A traditional meta-analysis and several subgroup analyses were conducted using traditional meta-analysis with relative risk (RR), trial sequential analysis, and meta-regression analysis.

RESULTS

43 RCTs met our inclusion criteria giving a total of 3277 patients in both control and treatment arms. There was a significant reduction in the risk of CIN in the NAC treated group compared to control (OR 0.666; 95% CI, 0.532-0.834; I2=40.11%; p=0.004). Trial sequential analysis, using a relative risk reduction threshold of 15%, indicates that the evidence is firm.

CONCLUSIONS

The results of the present paper support the use of NAC in the prevention of CIN in patients undergoing CAG±PCI. Future studies should focus on the benefits of NAC amongst subgroups of high-risk patients.

摘要

背景

已有大量研究探讨N-乙酰半胱氨酸(NAC)在预防接受冠状动脉造影(CAG)且有或无经皮冠状动脉介入治疗(PCI)患者的造影剂肾病(CIN)方面的有效性。然而,由于文献结果差异极大,关于NAC预处理的有效性仍未达成共识。

目的

本研究旨在进行荟萃分析和试验序贯分析,以确定术前使用NAC对降低接受CAG和/或PCI患者CIN发生率的影响。

方法

进行系统的文献检索,纳入所有比较NAC与对照组作为CAG和/或PCI预处理的随机对照试验(RCT)。使用传统荟萃分析、相对危险度(RR)、试验序贯分析和荟萃回归分析进行传统荟萃分析和多个亚组分析。

结果

43项RCT符合我们的纳入标准,对照组和治疗组共有3277例患者。与对照组相比,NAC治疗组CIN风险显著降低(OR 0.666;95%CI,0.532 - 0.834;I2 = 40.11%;p = 0.004)。试验序贯分析使用15%的相对危险度降低阈值,表明证据确凿。

结论

本文结果支持在接受CAG±PCI的患者中使用NAC预防CIN。未来的研究应关注NAC在高危患者亚组中的益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验